Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-4]
• Recurrent Clostridioides difficile Infection (rCDI) Reduction: Bezlotoxumab (BEZ) significantly reduced rCDI rates compared to standard care (SOC), with a pooled rCDI rate of 15.8% in BEZ-treated patients versus 28.9% in those receiving SOC, demonstrating a relative risk (RR) of 0.57 (95% CI: 0.45–0.72).
• MODIFY Trial Findings: In the MODIFY trials, BEZ was associated with a 10.0% absolute reduction in rCDI risk compared to placebo (16.5% vs. 26.6%; 95% CI -14.0 to -6.0; p<0.0001), with a number needed to treat (NNT) of 10 to prevent one rCDI event.
• Comparative Effectiveness with FMT and Other Interventions: Bezlotoxumab showed similar effectiveness to fecal microbiota transplantation (FMT) in rCDI resolution but with significantly lower rates of diarrhea compared to FMT, particularly when used with standard antibiotic therapy (SAT).
• Mortality and Heart Failure Risk: No significant differences in overall mortality or heart failure risk were observed in patients receiving bezlotoxumab (BEZ) compared to standard care (SOC), though caution was noted for patients with a history of congestive heart failure.
• Adverse Events (AEs): Bezlotoxumab with standard antibiotic therapy (SAT) was associated with significantly lower rates of non-serious diarrhea compared to fecal microbiota transplantation (FMT), which showed a higher incidence of this AE.
• No population types or subgroups information is available.